| pubmed-article:6404979 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C0015780 | lld:lifeskim |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C0019572 | lld:lifeskim |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C0037982 | lld:lifeskim |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:6404979 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:6404979 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6404979 | pubmed:dateCreated | 1983-6-10 | lld:pubmed |
| pubmed-article:6404979 | pubmed:abstractText | The effect of spironolactone on female hirsutism was studied in 18 patients. The drug was administered at the dose of 400 mg for the first ten days and 300-200 mg later on in a first group of women (Group A); a second group (Group B) was given 200 mg spironolactone for the whole length of therapy. A significant decrease of the index of Ferriman and Gallwey (p = 0.01) was noted from the 100th day of treatment; acne and seborrhoea improved concomitantly. Plasma total testosterone values fell from 0.64 +/- 0.24 ng/ml to 0.32 +/- 0.12 ng/ml (p = 0.002) during the first 5 days only in the patients of Group A; in the other patients no significant changes were observed. PRL did not significantly change from pretreatment values; FSH and LH values at the 5th, 10th, and 15th day of therapy did not show a uniform course in both groups. On the basis of these results spironolactone administration appears promising in the therapy of female hirsutism. | lld:pubmed |
| pubmed-article:6404979 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6404979 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404979 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6404979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404979 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404979 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6404979 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:6404979 | pubmed:issn | 0391-4097 | lld:pubmed |
| pubmed-article:6404979 | pubmed:author | pubmed-author:MolinattiG... | lld:pubmed |
| pubmed-article:6404979 | pubmed:author | pubmed-author:MessinaMM | lld:pubmed |
| pubmed-article:6404979 | pubmed:author | pubmed-author:ManieriCC | lld:pubmed |
| pubmed-article:6404979 | pubmed:author | pubmed-author:BiffignandiPP | lld:pubmed |
| pubmed-article:6404979 | pubmed:author | pubmed-author:NoviR FRF | lld:pubmed |
| pubmed-article:6404979 | pubmed:author | pubmed-author:MassucchettiC... | lld:pubmed |
| pubmed-article:6404979 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6404979 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:6404979 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6404979 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6404979 | pubmed:pagination | 23-7 | lld:pubmed |
| pubmed-article:6404979 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:meshHeading | pubmed-meshheading:6404979-... | lld:pubmed |
| pubmed-article:6404979 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6404979 | pubmed:articleTitle | Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. | lld:pubmed |
| pubmed-article:6404979 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6404979 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6404979 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6404979 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6404979 | lld:pubmed |
